Jerry Mendell Award for Translational Science

Nominations for the 2020 Jerry Mendell Award are now open! Submit your nomination by emailing materials to

About the Award

This award, supported by Dr. Suku and Ann Nagendran, recognizes the extensive work required to bring gene and cell therapies to clinical trial. The award is named for Jerry Mendell, M.D., the first person to study viral mediated gene therapy for muscular dystrophy in humans. Mendell was also the principal investigator in the study of the gene transfer clinical trial for spinal muscular atrophy type 1, which led to the FDA approval of onasemnogene abeparvovec-xioi‎ (Zolegensma) in the United States in 2019.

Nomination Criteria

To be eligible for this award, a nominee must be:

  • An ASGCT member in good standing

  • Involved in the development, delivery, and follow-up of a clinical stage gene and/or cell therapy

  • Nominated by at least two ASGCT members in good standing

  • Available to give a presentation of their work at the ASGCT Annual Meeting

The nominee should be involved in the pre-clinical development and discovery of the work(s) that goes beyond delivery of the final product. Participation only in clinical trials will not suffice for this award. The recipient should be known for expertise in the clinical area of translational research.

The recipient of the will be announced in advance of the Annual Meeting and invited to deliver a lecture. The recipient will receive an honorarium of $2,000 and travel reimbursement.

Please submit a nomination letter of 500 words or less to


ASGCT Policy Summit

September 23-25, 2020